Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2003

View Archived Issues

Novel antibacterial DNA-binding agents presented by GeneSoft

New endothelin antagonists in early development at GSK

Merck researchers describe novel PTP1B inhibitors for diabetes and metabolic disorders

New antitumor daunorubicin derivatives designed by Pharmacia

Agouron claims new HIV protease inhibitors

Idec and Biogen to codevelop three Biogen oncology therapeutics

Elan agrees to sell primary care franchise to King

Biogen updates key product development

CuraGen reports progress in 2002

Phase I results for trastuzumab with IL-2 in nonhematological cancer

Clinical use of a humanized anti-IL-6R monoclonal antibody in rheumatoid arthritis

Gabapentin safe and effective in reducing pain of Guillain-Barre syndrome

Regeneron reports progress of Axokine and other programs

Recent developments at Seattle Genetics

Bayer and Aventis abandon plans for biologicals joint venture

NIH grant supports Cerebril trials

Enrollment completed in phase III Tarceva trial in refractory NSCLC

ALVAC-CEA/B7.1 under investigation in two colorectal cancer trials

NDA filing planned for PDT therapy for AMD

Marketing clearance sought for Estorra for insomnia

BioTransplant and Catholic University of Louvain attempt to resolve dispute regarding MEDI-507

First biologic therapy for psoriasis approved by FDA

Aventis identifies nonpeptide, orally active Ang-(1-7) agonist

Approval of micafungin in the U.S. may be delayed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...